PER-047-00已完成未知
OPEN MULTICENTRIC CLINICAL STUDY TO EVALUATE THE LONG-TERM SECURITY IN 4 MG OF ZOMETA (ZOLEDRONATE) IN PATIENTS WITH METASTASIC BONE INJURIES FROM BREAST CANCER OR MULTIPLE MYELOMA
OVARTIS BIOSCIENSES PERU S.A.,0 个研究点目标入组 0 人开始时间: 2000年8月8日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Signed informed consent
- •Patients who have completed the 6 cycles of treatment with Aredia® or Zometa® from the central study
- •Performance status O, I, II (WHO Classification)
- •Normal corrected serum calcium level or mild hypercalcemia
排除标准
- •Patients with abnormal renal function evidenced either by a serum creatinine determination 1.5 times or more above the normal upper limit or by a calculated creatinine clearance of 60 mL / minute or less.
- •Pregnancy and lactation
- •Women of potential pregnancy age who are not under some medically recognized method of contraception
- •Persons who, in the investigator´s judgment, are unlikely to cooperate fully during the study
- •People who are participating simultaneously in studies with drugs, indications or non-approved treatment regimens. People who are participating in studies with approved drugs in approved indications are allowed using approved treatment regimens.
研究者
相似试验
进行中（未招募）
1 期
An Open-label, Multicenter Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of AEB1102 in Patients with Arginase I DeficiencyEUCTR2018-003163-67-PTAeglea Biotherapeutics, Inc.14
进行中（未招募）
1 期
An Open-label, Multicenter Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of AEB1102 in Patients with Arginase I DeficiencyArginase 1 deficiency HyperargininemiaMedDRA version: 20.0 Level: PT Classification code 10062695 Term: Arginase deficiency System Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2018-003163-67-GBAeglea Biotherapeutics, Inc.14
进行中（未招募）
不适用
An Open Label, Multicentre Study to Evaluate the Long Term Safety of Prolonged Release (PR) OROS Methylphenidate (18, 36, 54, 72 and 90 mg/day) in Adults with Attention Deficit/Hyperactivity Disorder - Lamda extensioAttention Deficit-Hyperactivity Disorder (ADHD)MedDRA version: 7.1Level: LLTClassification code 10003735EUCTR2005-004037-18-ESJanssen-Cilag Medical Affairs EMEA250
进行中（未招募）
不适用
An Open Label, Multicentre Study to Evaluate the Long Term Safety of Prolonged Release (PR) OROS Methylphenidate (18, 36, 54, 72 and 90 mg/day) in Adults with Attention Deficit/Hyperactivity Disorder - Lamda extensioEUCTR2005-004037-18-DEJanssen-Cilag Medical Affairs EMEA160
进行中（未招募）
1 期
A Study with an active treatment to Assess the Long-term Safety of Weekly Intravenous Product in Subjects with Pulmonary Emphysema due to Alpha1-Antitrypsin DeficiencyEUCTR2015-004110-23-FIGrifols Therapeutics LLC250